Rabies is a zoonotic infectious disease caused by rabies virus (RABV), and its mortality rate is as high as 100%. Globally, an average of 60,000 people die from rabies each year. The most effective method to prevent and limit rabies is vaccination, but it is currently expensive and inefficient, consisting of a 3-dose series of injections and requiring to be immunized annually. Therefore, it is urgent to develop a single dose of long-acting rabies vaccine. In this study, recombinant rabies virus (rRABV) overexpressing interleukin-33 (IL-33) was constructed and designated as rLBNSE-IL33, and its effect was evaluated in a mouse model. The results showed that rLBNSE-IL33 could enhance the quick production of RABV-induced immune antibodies as early as three days post immunization (dpi) through the activation of dendritic cells (DCs), a component of the innate immune system. Furthermore, rLBNSE-IL33 induced high-level virus-neutralizing antibodies (VNA) production that persisted for 8 weeks by regulating the T cell-dependent germinal center (GC) reaction, thus resulting in better protection against rabies. Our data suggest the IL-33 is a novel adjuvant that could be used to enhance innate and humoral immune responses by activating the DC-GC reaction, and thus, rLBNSE-IL33 could be developed as a safe and effective vaccine for animals.
The H7N9 avian influenza virus first emerged in eastern China in the spring of 2013 and became epidemic nationwide, causing wide concern worldwide due to its rapid outbreak and spread. Currently, vaccination remains the best way to prevent and control the spread of H7N9 influenza, and adjuvants are indispensable for the development of inactivated vaccines. Therefore, it is of great significance to develop efficient and inexpensive novel H7N9 influenza vaccine adjuvants. In this study, we constructed OX40L/Fc and H7N9 whole inactivated virus (WIV) co-immunized mice model and evaluated the efficacy of OX40L as an immune adjuvant in co-immunized mice. Mice co-immunized with H7N9 WIV + OX40L/Fc produced more T follicular helper cells (Tfh), germinal center (GC) B cells, and plasma cells (PCs) than mice immunized with the vaccine alone. This suggested that OX40L could improve protective antibody responses after co-immunization with H7N9 WIV by affecting T cell-dependent humoral immune responses. Overall, our results reveal that OX40L has a good adjuvant effect on H7N9 WIV vaccine.